Effects of Severe Negative Energy Balance on Inflammation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03524690 |
|
Recruitment Status :
Completed
First Posted : May 15, 2018
Last Update Posted : April 22, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Inflammation | Dietary Supplement: Energy Balance Dietary Supplement: Negative Energy Balance | Not Applicable |
Endurance exercise elicits skeletal muscle and systemic inflammation. Inflammation in response to endurance exercise is normally attenuated with adequate rest and recovery as skeletal muscle adapts with training. However, performing repeated bouts of prolonged and unaccustomed, muscle damaging (i.e., eccentric loading) endurance exercise may be detrimental to performance and limit the adaptive responses to exercise by diminishing the absorption of key nutrients. Warfighters are commonly exposed to such exercise bouts during sustained training and combat operations, the effects of which may be exacerbated by negative energy balance. Therefore, to define the putative role of energy balance on systemic inflammation, we will conduct a controlled laboratory study that simulates the physiological stressors imposed during sustained military training and combat operations to determine if systemic inflammation is exacerbated by underfeeding.
Twenty-six male, non-obese (body mass index 19.9-29.9 kg/m2), physically active adults will be recruited to participate in a 32 d, longitudinal study. The study is comprised of four sequential phases: 1) a 96 h testing period, 2) a 7 day recovery period (Recovery 1), 3) a second, 96 h testing period, and 4) a 14 d recovery period (Recovery 2). During testing, subjects will be randomized to consume either sufficient food (combat rations) to maintain energy balance or will be provided a restricted amount of food to elicit severe negative energy balance. Mineral absorption studies and will be conducted during each testing condition, energy balance and energy negative balance. This design will test the hypothesis that maintaining energy balance will attenuate systemic inflammation and its potential negative effects on whole-body metabolic homeostasis in response to physiological stressors.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 13 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Intervention Model Description: | Randomized, cross-over controlled trial |
| Masking: | None (Open Label) |
| Primary Purpose: | Basic Science |
| Official Title: | Effects of Severe Negative Energy Balance on Inflammation During a Simulated Military Operation |
| Actual Study Start Date : | February 13, 2019 |
| Actual Primary Completion Date : | October 8, 2019 |
| Actual Study Completion Date : | October 8, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: SUSOPS Balance
Volunteers provided sufficient food to maintain energy balance.
|
Dietary Supplement: Energy Balance
Energy Balance Sufficient food provided to maintain energy balance. |
|
Experimental: SUSOPS Negative Balance
Volunteers provided insufficient food to maintain energy balance resulting in negative energy balance.
|
Dietary Supplement: Negative Energy Balance
Negative Energy Balance Insufficient food provided to maintain energy balance resulting in negative energy balance. |
- The effects of a simulated military operation on systemic inflammation [ Time Frame: 6 hour measure ]Assessed using blood assays.
- The effects of energy balance and severe energy deficit on inflammation during a simulated military operation [ Time Frame: 6 hour measure ]Assessed using mineral absorption from stable isotopes.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 39 Years (Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Men who are active duty military, aged 18 - 39 years
- Weight stable in the past 2 months (± 2.27 kg)
- Healthy without evidence of chronic illness, medication use, or musculoskeletal injury as determined by the USARIEM Office of Medical Support and Oversight (OMSO)
- Recreationally active (2-4 days per week aerobic and/or resistance exercise)
- Refrain from taking any pain-relievers (e.g., acetaminophen), nonsteroidal anti-inflammatory drugs (e.g., aspirin, Advil®, Aleve®, Naprosyn®), or any other aspirin-containing product for 10 days before starting and at least 5 days after completing the study
- Refrain from the use of alcohol and nicotine for the duration of the study
- Willing to refrain from alcohol, smoking any nicotine product (includes e-cigarettes), vaping, chewing tobacco, caffeine, and dietary supplement use, and from consumption of probiotic-containing foods (e.g., yogurt) throughout the entire study period (vitamin/mineral supplements cannot be taken for at least 2 weeks before starting the study)
- Supervisor approval for non-HRV Active Duty Military working within the US Army Natick Soldier Systems Center
- Reports having a bowel movement at least as frequently as every-other-day
Exclusion Criteria:
- Musculoskeletal injuries that compromise exercise capability
- Metabolic or cardiovascular abnormalities (e.g., kidney disease, diabetes, cardiovascular disease, etc.)
- History of any disease or abnormality of the gastrointestinal tract including (but not limited to) diverticulosis, diverticulitis and inflammatory bowel disease, peptic ulcer disease, Crohn's disease, ulcerative colitis; or previous gastrointestinal surgery
- Anemic (plasma ferritin < 40 µg/L, hemoglobin < 13 g/dL) and Sickle Cell Anemia/Trait
- C-reactive protein (CRP) > 5 mg/dL
- Abnormal PT/PTT test or problems with blood clotting
- History of complications with lidocaine
- Evidence of any physical, mental, and/or medical conditions that would make the proposed studies relatively more hazardous as determined by OMSO
- Present condition of alcoholism or other substance abuse issues; use of anabolic steroids
- Blood donation within 4 months of beginning the study
- Oral antibiotic use within 3 months of participation
- Colonoscopy within 3 months of participation
- Use of laxatives, stool softeners, or anti-diarrheal medications more than once/month
- Currently using benzodiazepines, anti-depressants or anti-histamines
- Pacemaker or other implanted electronic medical device
- Are unwilling or unable to eat study diets and foods provided and/or follow exercise prescriptions
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03524690
| United States, Massachusetts | |
| US Army Research Institute of Environmental Medicine | |
| Natick, Massachusetts, United States, 01760 | |
| Principal Investigator: | Stefan M Pasiakos, PhD | Military Nutrition Division, USARIEM |
Documents provided by United States Army Research Institute of Environmental Medicine:
| Responsible Party: | United States Army Research Institute of Environmental Medicine |
| ClinicalTrials.gov Identifier: | NCT03524690 |
| Other Study ID Numbers: |
18-06HC |
| First Posted: | May 15, 2018 Key Record Dates |
| Last Update Posted: | April 22, 2020 |
| Last Verified: | April 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Inflammation Pathologic Processes |

